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Abstract
Objective: Photodynamic diagnosis (PDD) of superﬁ  cial bladder cancer decreases recurrence rates. We present oncological 
results of a randomized, prospective study, comparing transurethral resection (TUR) performed under conventional white 
light (WL) with PDD. The follow-up period is the longest reported to date. As costs might be reimbursed by prolonged 
recurrence-free survival in certain patients cost analysis in regard to risk-groups was performed.
Material and methods: Using chi-square test and log-rank test we compared recurrence rates of 103 patients after 
WL-TUR and of 88 patients after PDD-TUR. Cost analysis was performed according to risk-groups of recurrence.
Results: Mean follow-up was 99 months. Recurrence rate was 57% in WL vs. 28% in PDD (p  0.001). Costs incurred 
by subsequent TUR averaged € 2310 per WL patient vs. € 713 per PDD patient. Savings per patient by PDD amounted 
to € 1597. PDD costs were reimbursed in low, intermediate and high risk patients, respectively.
Conclusions: PDD-TUR is signiﬁ  cantly superior to conventional WL-TUR in terms of recurrence rate. While economic 
beneﬁ  t is most prominent in intermediate risk patients, PDD related costs are reimbursed in all risk-groups.
Keywords: superﬁ  cial bladder cancer, urothelial carcinoma, photodynamic, transurethral resection, recurrence rate, cost 
analysis
Introduction
About 70% of transitional cell carcinomas of the bladder are superﬁ  cial.
1 Despite macroscopically 
complete tumor removal including muscular tissue, over two-thirds of patients undergoing transurethral 
resection (TUR) with white light experience recurrence. In approximately 15% of cases, stage progression 
to muscle-invasive tumors is observed requiring radical surgery.
2 The high recurrence rate has been 
partly attributed to the poor macroscopical visibility of scattered tumor tissue, e.g. carcinoma in situ 
(CIS), that might be overlooked in conventional TUR leading to recurrence.
Urological research has long sought a practicable technique improving recognition of malignant 
urothelial tumors. In 1992, one such clinically applicable procedure was introduced, intravesical 
application of 5-aminolevulinic acid (5-ALA) with subsequent photodynamic diagnostics (PDD).
3 
PDD has been reported to facilitate detection of ﬂ  at, small papillary and remnant lesions poorly 
visible under conventional white light.
4,5 5-ALA instilled into the bladder prior to TUR is metabo-
lized to protoporphyrin-IX in the urothelial cell. Whilst in normal cells, the enzyme ferrochelatase 
transforms this ﬂ  uorescent agent into heme, this step is impaired in tumor cells, inﬂ  amed or granu-
lating tissue: Protoporphyrin-IX accumulates producing reddish ﬂ  uorescence under blue light 
(345–440 nm).
6
The ﬁ  rst publications on PDD mainly focused on its diagnostic value with sensitivities over 97% 
and speciﬁ  ties ranging between 35% and 70%.
5,7–12 The high sensitivity lead some authors to call for 
general application of PDD in the diagnosis of bladder cancer.
13 Critics however rejected PDD due to 
its low speciﬁ  ty.54
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Randomized, prospective clinical trials
14,15 
however reported a statistically signiﬁ  cant reduc-
tion of the residual tumor rate using PDD. Our 
institution performed a randomized prospective 
study in order to clarify whether recurrence rate 
could be reduced by PDD.
Superﬁ  cial bladder cancer imposes enormous 
costs on public health systems due to its life-long 
character. By reducing the frequency of recurrences 
PDD has been suggested to ease this economic 
burden.
16,17 However as PDD is related to speciﬁ  c 
expenditures its use may not be justiﬁ  ed on a larger 
scale but in those patients with obvious beneﬁ  t 
from PDD only. Multifocality, previous bladder 
cancer, tumor stage and histologic grade have been 
recognized as predictors of recurrences and have 
been reported to stratify risk-groups.
18
In the present study we report the longest expe-
rience with recurrences following WL versus PDD. 
Hospitals are compensated for surgical procedures 
according to the DRG (diagnosis related groups) 
system providing equal and transparent funding. 
We analyzed all costs related to subsequent TURs 
and the use of PDD. Of focal interest was the ques-
tion if reimbursement of PDD-related expenditures 
can be achieved in all risk-groups and so every 
patient with superﬁ  cial bladder cancer could proﬁ  t 
from the use of PDD.
Material and Methods
Ethical approval and written informed consent 
from each patient were obtained. From May 1997 
until August 2000, 301 patients presenting with 
lesions suspicious for bladder cancer in urethro-
cystoscopy were randomized into TUR with 
conventional white light cystoscopy (n = 150) or 
TUR supplemented by PDD with 5-ALA (n = 151) 
as previously reported.
19
Six weeks after the initial TUR all patients 
underwent repeat WL resection to evaluate 
residual tumor rate. All specimen were graded 
according to the 1994 WHO classiﬁ  cation and 
staged according to the 1997 TNM system.
20,21 
Patients with muscle-invasive urothelial carcinoma 
(T2) or benign histological findings were 
excluded from the study. Intravesical recurrence 
prophylaxis was performed according to the guide-
lines of the American Urological Association 
(AUA) for treatment of superﬁ  cial bladder cancers. 
Whilst solitary primary tumors pTaG1–G2 did not 
receive recurrence prophylaxis, patients with 
multifocal bladder lesions staged pTaG1–G3 and 
pT1G1–G2 received mitomycin (MMC) treatment. 
Primary pT1G3 tumors, carcinoma in situ plus 
patients who did not respond to MMC received 
instillation therapy with 6 weekly courses of bacil-
lus Calmette-Guérin (BCG).
22 In the case of recur-
ring pT1G3 and Cis, patients were advised to 
undergo radical cystectomy. The patients attended 
follow-up examinations involving white light 
cystoscopy and cytology at quarterly intervals, the 
ﬁ  rst follow-up being 3 months after secondary 
transurethral resection. Recurrence was veriﬁ  ed 
by TUR and histopathology.
Recurrence rates were evaluated for each risk-
group as deﬁ  ned by respective guidelines issued 
by the European Association of Urology (EAU).
18 
Expenditures related to subsequent TURs were 
calculated based on the current German DRGs. 
Costs related to PDD were evaluated. Chi-square 
and log-rank tests were used to determine statistical 
signiﬁ  cance between the groups, values 5% were 
considered signiﬁ  cant.
Results
Oncological long-term outcome
Data from 103 of the 150 patients in the white 
light arm (WL) could be evaluated, 47 were 
excluded lacking malignancy (n = 21), presenting 
with muscle-invasive urothelial carcinoma 
(n = 24) or refusing post-operative follow-up 
(n = 2). Of the 151 patients randomized into 
the fluorescent diagnostic study arm (PDD), 
88 could be evaluated after excluding 63 patients 
(38 + 23 + 2).
Mean age was 70 years (range: 32 to 79 years) 
and 68 years (range: 31 to 88 years) in WL and 
PDD, respectively. Distribution of gender, tumor 
stage, grade and prognostic groups according to 
the EAU was similar between the two patient 
groups. However distribution of multifocality was 
disadvantageous for PDD (Table 1). Residual 
tumor rate was 25.2% in WL versus 4.5% in PDD 
(p  0.001). Reresection did not show statistically 
signiﬁ  cant differences in upgrading between both 
groups. Also percentage of prophylaxis—with 
MMC in 30% (WL) and 36% (PDD), respectively, 
and with BCG in 29% (WL) and 36% (PDD), 
respectively—did not show statistically signiﬁ  cant 
differences between the risk-groups in both study 
arms (p = 0.81).
Mean follow-up was 102 months (76–110 
months) in WL and 98 months (73–108 months) 55
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in PDD, respectively. Throughout the follow-up 
period 57% recurrences were observed in WL 
versus 28% in PDD (Fig. 1; log rank test: 
p  0.001). The recurrence rate after 25, 50, 75 
and 100 months in WL was 32%, 39%, 48% and 
57%, respectively, compared to 9%, 17%, 22% and 
28% in PDD. Superiority of PDD was conﬁ  rmed 
for all risk-groups in sub-group analysis (Table 2). 
4 patients in WL (3.9%) and 3 patients in PDD 
group (3.4%) developed muscle-invasive progres-
sion with need for cystectomy.
Economic long-term results
During follow-up, 238 further TURs were 
performed due to suspicious findings in WL 
(2.3 per patient), as opposed to 104 TURs (1.2 per 
patient) in PDD. Deducting TURs revealing false 
positive lesions, 1.32 and 0.33 TURs per patient 
were performed for malign ﬁ  ndings in WL and 
PDD, respectively.
5-ALA was marketed at € 95 per instillation 
and material and time required for single-use 
catheterization summed up to € 30. Considering a 
depreciation over 10 years and 50 uses per year, 
€ 10 were determined as equipment related costs 
per use concerning equipment costs at about 
€ 5000. Thus PDD-related costs amounted to € 135 
per patient. In the current German DRG system 
TUR burdens the public health care system with 
€ 1750. Considering resections with true positive 
findings only TUR related expenditures 
were € 2310 (1.32 × DRG) in WL versus € 713 
(0.33 × DRG + € 135) in PDD after 100 months, 
respectively. Thus about 192 € (€ 1597:100 × 12) 
were saved per PDD patient per year followed-up 
in the present series.
In the subgroup analysis an economic advantage 
of PDD was noted in all risk-groups (Fig. 2). How-
ever it was most pronounced in intermediate risk 
patients, as € 1405, € 2245 and € 1738 were saved 
by the use of PDD in low, intermediate and high 
risk patients, respectively.
Discussion
Overlooking of smaller ﬂ  at and papillary lesions in 
conventional white light during primary transurethral 
resection poses a major problem in the treatment of 
bladder cancer. Various studies report residual tumor 
Table 1. Characteristics of study patients.
WL arm 
(n = 103)
PDD arm 
(n = 88)
p value
First occurrence of BC [%] 81.6 69.3 p = 0.06
Staging [%] p = 0.75
 pTaG1 41.7 42.0
 pTaG2 28.2 30.7
 pTaG3 1.0 2.3
 pT1G1 0 1.1
 pT1G2 12.6 6.8
 pT1G3 11.7 11.4
 pTis 4.9 5.7
Focality [%] p = 0.03
 solitary  tumor 76.7 62.5
 multifocal  tumors 23.3 37.5
Risk groups [%] p = 0.39
   low (solitary/ﬁ  rst occurred 
pTaG1/2, pT1G1)
48.5 35.2
   intermediate (all other stages) 34.0 45.5
   high (pTaG3, pT1G3, pTis) 17.5 19.3
Abbreviations: BC, bladder cancer; PDD, photodynamic diagnosis; WL, white light cystoscopy.56
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rates after TUR of superficial bladder tumors 
between 30% and 70%.
2,12,23–25 Thus repeat resection 
has been advocated in some cases approximately 6 
weeks after primary TUR for monitoring and 
completion of tumor resection.
26 The outcome of 
repeat resection can serve as a parameter for the 
quality of the 5-aminolevulinic acid (5-ALA)-
induced ﬂ  uorescence diagnostics. The comparison 
of residual tumor rates after WL and PDD was the 
first test parameter in the presented controlled, 
randomized clinical trial. In the WL arm residual 
tumor rate was 25.2% versus a mere 4.5% in PDD 
(p  0.001).
19 This ﬁ  nding is in accordance with 
previous studies by Riedl et al. and Kriegmair 
et al.
14,27 The rate of upgradings in reresection did not 
differ statistically signiﬁ  cant between both groups.
However in contrast to a reduction in residual 
tumor rate only reduction in recurrence rate poses a 
clinically relevant advantage. A ﬁ  rst interims analysis 
of this study after 42 months showed PDD to reduce 
recurrence rates.
5 Daniltchenko et al. described 
recurrence rates after 60 months of 59% in PDD and 
75% in WL, respectively.
16 However, only long-term 
data can evaluate the true beneﬁ  t of PDD. Thus we 
present the longest follow-up period reported today. 
After a follow-up of 100 months patients in the PDD 
arm showed a recurrence rate of 28% as opposed to 
57% in the WL arm (p  0.001). This ﬁ  nding was 
consistent in all risk-groups.
While the oncological outcome seems to beneﬁ  t 
from PDD the reduction in tumor recurrences might 
also reduce the economic burden imposed on public 
health systems by subsequent surgery. In a long-term 
analysis, costs per patient were reduced by about 
€ 1597. The additional costs of € 135 related to PDD 
are reimbursed by far. While previous studies with 
shorter follow-up periods have not taken the inﬂ  uence 
of risk factors into account, the present contribution 
Figure 1.   Analysis of recurrence rates after conventional white light (WL) transurethral resection and photodynamic diagnostics (PDD) in 
study patients.
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Table 2. Recurrence rates of study patients after follow-up periods of 25, 50, 75 and 100 months stratiﬁ  ed in low, 
intermediate and high risk patients.
WL arm 
[%]
PDD arm 
[%]
p value 
(log-rank test)
Study patients (WL n = 103, PDD n = 88) p  0.001
  recurrence rate after 25 months 32 9
  recurrence rate after 50 months 39 17
  recurrence rate after 75 months 48 22
  recurrence rate after 100 months 57 28
High risk group (WL n = 18, PDD n = 17) p = 0.02
  recurrence rate after 25 months 48 18
  recurrence rate after 50 months 61 31
  recurrence rate after 75 months 79 39
  recurrence rate after 100 months 85 56
Inter risk group (WL n = 35, PDD n = 40) p = 0.02
  recurrence rate after 25 months 40 14
  recurrence rate after 50 months 49 20
  recurrence rate after 75 months 58 30
  recurrence rate after 100 months 60 33
Low risk group (WL n = 50, PDD n = 31) p = 0.003
  recurrence rate after 25 months 16 2
  recurrence rate after 50 months 28 5
  recurrence rate after 75 months 45 13
  recurrence rate after 100 months 48 19
Abbreviations: PDD, photodynamic diagnosis; WL, white light cystoscopy.
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stratiﬁ  ed economic analysis according to risk factors 
as deﬁ  ned by the EAU.
9,17,18 We were able to show 
that PDD holds an economic beneﬁ  t and PDD related 
costs are reimbursed even in low risk cases.
Recently 5-ALA ester hexaminolevulinic acid 
(Hexvix, GE-Healthcare, Munich, Germany) was 
licensed in Europe. It has been suggested to promote 
the results of 5-ALA as the standard in PDD.
28
In conclusion photodynamic diagnostics 
signiﬁ  cantly reduces recurrence rates in the longest 
follow-up period reported to date. This effect was 
apparent independently of the patients` prognostic 
risk-group. PDD seems to hold oncological and 
economical beneﬁ  ts. In the present series subsequent 
costs were reduced by almost € 1600 per patient by 
the use of PDD and reimbursement of PDD-related 
costs was achieved even in low risk patients by far.
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